What if you could inject a significantly smaller dose of toxic chemotherapy directly into a malignant tumor site and stop its growth? The potential benefits range from greatly reduced drug side effects, to a complete remission of the disease, to an inoculation against future cancer growth. For Intensity Therapeutics, these results have already been shown in mice. The company is now raising funds to advance to clinical trials, which have been fast-tracked by the U.S. Food and Drug Administration.
Intensity Therapeutics, Inc. is a biotechnology company whose mission is to greatly extend the lives of patients with solid tumor cancers. The company has partnered with the National Cancer Institute to test its pioneering new immunotherapy approach to treat cancer called in situ vaccination.
The Company’s products consist of proprietary formulations of proven chemotherapy drugs that are injected directly into tumors. Early preclinical data show that these products, when injected directly into tumors, result in significantly greater tumor growth inhibition and increased survival compared to conventionally IV-delivered chemotherapy. The technology attenuates (kills) a tumor in a manner that allows for the adaptive immune system to recognize the cancer, to attack untreated tumors, and to prevent cancer from returning.